Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission

Despite substantial progress in reducing the global impact of many non-communicable diseases, including heart disease and cancer, morbidity and mortality due to chronic respiratory disease continues to increase.

Compared with other diseases with similar or less morbidity and mortality, the investment of financial and intellectual resources from both the public and private sector to advance understanding of COPD, reduce exposure to known risks, and develop new therapeutics has been woefully inadequate.

Autores: Prof Daiana Stolz, MD
Takudzwa Mkorombindo, MD
Desiree M Schumann, PhD
Prof Alvar Agusti, MD
Prof Samuel Y Ash, MD
Prof Mona Bafadhel, PhD
Prof Chunxue Bai, MD
Prof James D Chalmers, MD
Prof Gerard J Criner, MD
Prof Shyamali C Dharmage, PhD
Prof Frits M E Franssen, PhD
Prof Urs Frey, MD
Prof MeiLan Han, MD
Prof Nadia N Hansel, MD
Prof Nathaniel M Hawkins, MD
Prof Ravi Kalhan, MD
Prof Melanie Konigshoff, PhD
Prof Fanny W Ko, MD
Trisha M Parekh, DO
Pippa Powell, PhD
Prof Maureen Rutten-van Mölken, PhD
Prof Jodie Simpson, PhD
Prof Don D Sin, MD
Prof Yuanlin Song, MD
Prof Bela Suki, PhD
Prof Thierry Troosters, PhD
Prof George R Washko, MD